Likely a matter of time for Amyloid-β immunotherapy

Amyloid-β peptide (Aβ) deposition in the brain is an early feature of Alzheimers’ disease. In a phase II clinical trial recently published in The New England Journal of Medicine, Mintun and colleagues report on the safety and efficacy of an antibody targeting Aβ peptide in amyloid plaques for the tr...

Descripción completa

Detalles Bibliográficos
Autor principal: Cunha, Andreia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985757/
https://www.ncbi.nlm.nih.gov/pubmed/35602205
http://dx.doi.org/10.1038/s43856-021-00010-6
_version_ 1784682415168421888
author Cunha, Andreia
author_facet Cunha, Andreia
author_sort Cunha, Andreia
collection PubMed
description Amyloid-β peptide (Aβ) deposition in the brain is an early feature of Alzheimers’ disease. In a phase II clinical trial recently published in The New England Journal of Medicine, Mintun and colleagues report on the safety and efficacy of an antibody targeting Aβ peptide in amyloid plaques for the treatment of participants with early symptomatic Alzheimer’s disease.
format Online
Article
Text
id pubmed-8985757
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-89857572022-05-20 Likely a matter of time for Amyloid-β immunotherapy Cunha, Andreia Commun Med (Lond) Research Highlight Amyloid-β peptide (Aβ) deposition in the brain is an early feature of Alzheimers’ disease. In a phase II clinical trial recently published in The New England Journal of Medicine, Mintun and colleagues report on the safety and efficacy of an antibody targeting Aβ peptide in amyloid plaques for the treatment of participants with early symptomatic Alzheimer’s disease. Nature Publishing Group UK 2021-06-30 /pmc/articles/PMC8985757/ /pubmed/35602205 http://dx.doi.org/10.1038/s43856-021-00010-6 Text en © Springer Nature Limited 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Highlight
Cunha, Andreia
Likely a matter of time for Amyloid-β immunotherapy
title Likely a matter of time for Amyloid-β immunotherapy
title_full Likely a matter of time for Amyloid-β immunotherapy
title_fullStr Likely a matter of time for Amyloid-β immunotherapy
title_full_unstemmed Likely a matter of time for Amyloid-β immunotherapy
title_short Likely a matter of time for Amyloid-β immunotherapy
title_sort likely a matter of time for amyloid-β immunotherapy
topic Research Highlight
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985757/
https://www.ncbi.nlm.nih.gov/pubmed/35602205
http://dx.doi.org/10.1038/s43856-021-00010-6
work_keys_str_mv AT cunhaandreia likelyamatteroftimeforamyloidbimmunotherapy

Ejemplares similares